Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 1/20 | 0.46 |
| ▸ | GABRD | O14764 | 1/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.46 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.46 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.46 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.46 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.46 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.46 |
| ▸ | GABRE | P78334 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.46 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.46 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.46 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4713947 | 0.98 | GABRP (0.45) | GABRPGABRDGABRA1TSHRGABRB1 | |
| SCHEMBL6184114 | 0.88 | GABRA5 (0.39) | GABRPGABRDGABRA1TSHRGABRB1 | |
| SCHEMBL1289738 | 0.84 | ALDH1A1 (0.47) | KDM4EALDH1A1PKMBCHEMEN1 | |
| SCHEMBL2545486 | 0.84 | TSHR (0.43) | GABRPGABRDGABRA1TSHRGABRB1 | |
| Hydrochloric Acid SCHEMBL1289689 | 0.82 | ALDH1A1 (0.46) | KDM4EALDH1A1PKMBCHEMEN1 | |
| SCHEMBL13058298 | 0.80 | BCHE (0.50) | KDM4EALDH1A1PKMBCHE | |
| SCHEMBL1053598 | 0.80 | BCHE (0.50) | KDM4EALDH1A1PKMBCHERAB9A | |
| SCHEMBL8791707 | 0.79 | MEN1 (0.61) | KDM4EALDH1A1OPRD1MEN1KMT2A | |
| SCHEMBL3628742 | 0.78 | BCHE (0.49) | KDM4EALDH1A1PKMBCHE | |
| SCHEMBL21362892 | 0.78 | BCHE (0.49) | KDM4EALDH1A1PKMBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115819328-A | Memantine urea derivative, preparation method thereof and application thereof in preparing medicine for treating soluble epoxide hydrolase mediated diseases | 沈阳药科大学 | 2023-03-21 | — | — | CN | claimed |
| US-12258316-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2025-03-25 | — | — | US | disclosed |
| CN-111187251-B | Pyridinoylpiperidine derivatives and their use | 广东东阳光药业有限公司 | 2023-06-09 | — | — | CN | disclosed |
| CN-115819328-A | Memantine urea derivative, preparation method thereof and application thereof in preparing medicine for treating soluble epoxide hydrolase mediated diseases | 沈阳药科大学 | 2023-03-21 | — | — | CN | disclosed |
| US-20220306579-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-09-29 | — | — | US | disclosed |
| US-11247969-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-02-15 | — | — | US | disclosed |
| US-20200290966-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-09-17 | — | — | US | disclosed |
| CN-111187251-A | Pyridylpiperidine derivatives and use thereof | 广东东阳光药业有限公司 | 2020-05-22 | — | — | CN | disclosed |
| US-10570092-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-02-25 | — | — | US | disclosed |
| US-10343995-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-07-09 | — | — | US | disclosed |
| US-7288657-B2 | Biphenyl-2-ylcarbamic acid or biphenyl-2-yluurea derivatives for treatment of respiratory system disorders; chronic obstructive pulmonary disease, asthma; antihistamines, bronchodilator agents; side effect reduction | THERAVANCE, INC. (US) | 2007-10-30 | — | — | US | disclosed |
| EP-1819692-A1 | 3-ETHYLIDENEHYDRAZINO SUBSTITUTED HETEROCYCLIC COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | Nissan Chemical Industries, Ltd. (JP) | 2007-08-22 | — | — | EP | disclosed |
| CN-1930125-A | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE INC (US) | 2007-03-14 | — | — | CN | disclosed |
| EP-1723114-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | Theravance, Inc. (US) | 2006-11-22 | — | — | EP | disclosed |
| CN-1280269-C | Aliphatic nitrogenous five-membered ring compound | TANABE SEIYAKU CO (JP) | 2006-10-18 | — | — | CN | disclosed |
| WO-2006062240-A1 | 3-ETHYLIDENEHYDRAZINO SUBSTITUTED HETEROCYCLIC COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2006-06-15 | — | — | WO | disclosed |
| WO-2005087738-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| US-20050203133-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. | 2005-09-15 | — | — | US | disclosed |
| CN-1468217-A | Aliphatic nitrogenous five-membered ring compounds | ������ҩ��ʽ���� | 2004-01-14 | — | — | CN | disclosed |
| CN-85106626-A | The preparation of 4-amino-2-phenyl-quinoline | — | 1987-03-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11247969-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | GABRP 1156/4885GABRD 405/4885GABRA1 286/4885 |
| US-20220306579-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM1, CHRM3 | GABRP 1156/4885GABRD 405/4885GABRA1 286/4885 |
| US-20050203133-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | GABRP 1156/4885GABRD 405/4885GABRA1 286/4885 |
| US-10343995-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | GABRP 1156/4885GABRD 405/4885GABRA1 286/4885 |
| US-10570092-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | GABRP 1156/4885GABRD 405/4885GABRA1 286/4885 |
| US-12258316-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | GABRP 1156/4885GABRD 405/4885GABRA1 286/4885 |
| US-20200290966-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM1, CHRM3 | GABRP 1156/4885GABRD 405/4885GABRA1 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.